Apogenix Receives FDA Orphan Drug Designation for Apocept™ to Treat Myelodysplastic Syndromes and Initiates Clinical Phase I Study
2/7/2013 10:18:04 AM
More...
|
Apogenix's Apocept™ for Glioblastoma Multiforme Named One of "Top 10 Projects to Watch"
11/6/2012 1:54:00 PM
More...
|
Apogenix: APG101 Exceeds Expectations With Controlled Phase II Clinical Trial in Treatment of Recurrent Glioblastoma
7/26/2012 10:01:36 AM
More...
|
Apogenix Receives Additional €2.3 Million BMBF Grant as Partner of the Biotech Cluster Rhine-Neckar
1/9/2012 2:40:12 PM
More...
|
Apogenix Raises €7.5 Million to Further Advance APG101 to Treat Glioblastoma and Other Tumors
1/5/2012 9:26:04 AM
More...
|
Apogenix Provides Update in the Ongoing Phase II Clinical Trial of APG101 to Treat Glioblastoma
1/24/2011 11:09:08 AM
More...
|
Apogenix: Death Receptor CD95 Promotes Tumour Growth
5/27/2010 11:14:10 AM
More...
|
Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma
1/11/2010 1:08:02 PM
More...
|
Apogenix Reports Positive Phase I Results on its Lead Compound AGP101
5/13/2009 1:12:25 PM
More...
|
Two Grants Totaling EUR 1.65 Million by the German Federal Ministry of Education and Research (BMBF) to Support Apogenix´ Research
9/22/2008 3:30:05 PM
More...
|
|